
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
caspase-6 CRISPR Activation Plasmid (h) | sc-402563-ACT | 20 µg | $397.00 | |||
caspase-6 CRISPR Activation Plasmid (h2) | sc-402563-ACT-2 | 20 µg | $397.00 |
CASP6 encodes caspase-6, a cysteine-aspartate protease that functions as an executioner caspase in regulated cell death and proteolytic remodeling of cellular substrates. Caspase-6 activity contributes to apoptotic signaling downstream of initiator caspases and intersects with pathways controlling cytoskeletal integrity, nuclear protein processing, and stress-responsive proteostasis. Altered CASP6 expression or activation has been associated with neurodegenerative processes, inflammatory signaling contexts, and apoptosis-related phenotypes observed in cancer biology. As a node within caspase cascades, caspase-6 is frequently used to interrogate cleavage-dependent mechanisms that shape cell fate decisions and tissue homeostasis.
caspase-6 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CASP6 expression without altering the underlying DNA sequence.
caspase-6 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CASP6 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CASP6 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous caspase-6 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CASP6 locus and enabling the study of caspase-6-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of caspase-6 pathway restoration in tumor cells with silenced or reduced CASP6 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.